FDA assembles adcomm to review GSK's Jemperli trial plans in rectal cancer

The FDA’s Oncologic Drugs Advisory Committee will meet this Thursday to discuss whether proposed studies would support an accelerated approval for GSK’s Jemperli in rectal cancer — despite initial concerns about the trial plans.